Landogrozumab
Landogrozumab
Landogrozumab (pronounced lan-doh-groh-zoo-mab) is a monoclonal antibody designed for the treatment of osteoporosis. It is a type of biopharmaceutical that works by inhibiting a protein known as sclerostin, which plays a key role in regulating bone growth.
Etymology
The name "Landogrozumab" is derived from the Latin words landa meaning "land", grozu meaning "growth", and mab which is a common suffix for monoclonal antibodies. This reflects the drug's function in promoting bone growth.
Usage
Landogrozumab is used in the treatment of osteoporosis, a condition that weakens bones and makes them more prone to fractures. It is particularly used in postmenopausal women who are at high risk of fractures.
Mechanism of Action
Landogrozumab works by binding to sclerostin and inhibiting its activity. Sclerostin is a protein that inhibits bone formation. By blocking its action, landogrozumab allows for increased bone formation and decreased bone resorption, leading to an overall increase in bone mass and strength.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Osteoporosis: A condition in which bones become weak and brittle.
- Sclerostin: A protein produced by osteocytes that inhibits bone formation.
- Biopharmaceutical: A type of drug produced using biotechnology.
External links
- Medical encyclopedia article on Landogrozumab
- Wikipedia's article - Landogrozumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski